Skip to search formSkip to main contentSkip to account menu

lucinactant Intratracheal Suspension [Surfaxin]

National Institutes of Health

Related topics

Related topics

2 relations
Surfaxin

Narrower (1)

lucinactant 30 MG/ML Intratracheal Suspension [Surfaxin]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Monographs: Lucinactant for the treatment of respiratory distress syndrome in neonates.
2009
2009
Lucinactant (Surfaxin ™ ) for prevention and treatment of respiratory distress syndrome in newborns
Respiratory distress syndrome, resulting from the deficiency of endogenous surfactant, remains a leading cause of mortality and… 
2005
2005
140 Preventing Respiratory Distress Syndrome: A Comparative Pharmacoeconomic Analysis of Lucinactant (Surfaxin) Versus Pooled Animal-Derived Surfactants
Background: Lucinactant (Surfaxin®) is the first available synthetic surfactant containing a peptide (sinapultide; KL4) that… 
2005
2005
134 Long-Term Outcomes of Lucinactant (Surfaxin) Vs. Animal-Derived and Synthetic, Non–Protein-Containing Synthetic Surfactants in Very Preterm Infants
Background: We have published results of two randomized, controlled trials comparing lucinactant (Surfaxin®), a new generation… 
2005
2005
406 Infants with Necrotizing Enterocolitis: Pharmacoeconomic Analysis of Lucinactant (Surfaxin) Versus Pooled Animal-Derived Surfactants in Preventing RDS
Background: Necrotizing enterocolitis (NEC) is a serious complication among pre-term infants. Surfactant replacement therapy can… 
2005
2005
137 Bradycardia/Desaturation/Apnea After Vaccination in the Very Low Birth Weight Newborns. A Prospective Study
Severe adverse reactions, i.e. apnea, bradycardia and desaturation, have been reported after DTP-Hib immunization in very preterm… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)